Windrum P, Morris T C M, Drake M B, Niederwieser D, Ruutu T
Department of Haematology, Belfast City Hospital, Belfast, Northern Ireland.
Bone Marrow Transplant. 2005 Oct;36(7):601-3. doi: 10.1038/sj.bmt.1705100.
The cryoprotectant dimethyl sulfoxide (DMSO) is known to have toxic side effects, yet guidelines for its use in stem cell transplantation do not exist. To assess current practice in the use of DMSO and the incidence of DMSO-related complications, a single page questionnaire was mailed to 444 EBMT centres involved in autologous transplantation. The responses from 97 centres showed a wide variation in practice between transplant units regarding the concentration of DMSO used, daily DMSO dose restriction and the use of cell washing. The overall incidence of DMSO toxicity was approximately one in 70 transplants and most cases were cardiovascular and respiratory in nature. There was a trend to reduced complication rates in centres using lower concentrations of DMSO or washing cells prior to return. A large-scale prospective study of the strategies for reduction in exposure to DMSO and reduction in toxic effects is required before guidelines in the use of DMSO in stem cell cryopreservation can be promulgated.
已知冷冻保护剂二甲基亚砜（DMSO）具有毒副作用，但目前尚无其在干细胞移植中使用的指南。为评估DMSO的当前使用情况以及与DMSO相关并发症的发生率，向参与自体移植的444个欧洲血液与骨髓移植协会（EBMT）中心邮寄了一份单页问卷。97个中心的回复显示，各移植单位在DMSO使用浓度、每日DMSO剂量限制以及细胞洗涤的使用方面，实际操作存在很大差异。DMSO毒性的总体发生率约为每70例移植中有1例，且大多数病例为心血管和呼吸系统问题。在使用较低浓度DMSO或在回输前洗涤细胞的中心，并发症发生率有降低的趋势。在颁布DMSO用于干细胞冷冻保存的指南之前，需要对减少DMSO暴露和降低毒性作用的策略进行大规模前瞻性研究。
